Resource utilization associated with the management of potential interactions between direct-acting antivirals for chronic hepatitis C treatment and cardiovascular and central nervous system drugs

Evaluation of the additional actions and resource utilization required for the management of potential drug-drug interactions in HCV patients showing cardiovascular and central nervous system comorbidities, treated with sofosbuvir/velpatasvir compared to glecaprevir/ pibrentasvir in routine clinical practice in Spain.

Authors: Esther Molina, Marta Torrens, Javier Ampuero, Carlos Roncero, Mar Alameda, Victoria Martín-Escudero, Neus Vidal-Vilar, Susana Aceituno, Ramón Morillo-Verdugo

Year: 2022

Download PDF

Subscribe to Outcomes´10

Name

E-mail

Responsible for the data: Outcomes'10, s.l.u., Purpose: Sending commercial communications. Legitimation: Art. 6.1 Consent of the interested party. Recipient: No data is transferred unless expressly authorised. You may exercise your rights on data protection (access, rectification, opposition, deletion, automated decisions, limitation of treatment, portability) by email at dpo@outcomes10.com. In any case, you can request the protection of the Spanish Data Protection Agency through its website www.aepd.es/. In addition, you can consult more information on the privacy policy

I have read and accepted the privacy policy